ライフサイエンスコーパス: serum sample

1 lective detection of HA protein in a chicken serum sample.

2 wed high discriminant capability in the real serum sample.

3 +/- 4.1% obtained from a spiked, real human serum sample.

4 s also evaluated to detect uric acid in real serum samples.

5 sess fast (<2 min) functional effects of the serum samples.

6 beta-d-glucan and 516 galactomannan tests on serum samples.

7 titer of a panel of SARS-CoV-2 convalescent serum samples.

8 ement as well as efficient handling of blood serum samples.

9 and low-molecular-weight proteins present in serum samples.

10 dy binding sites simultaneously from complex serum samples.

11 IgG titres against periodontal pathogens in serum samples.

12 the detection of NS1 DENV biomarker in human serum samples.

13 between 108.84% and 172.50% (n = 3) in human serum samples.

14 was demonstrated using (non-)clinical human serum samples.

15 e principal peach allergen (Pru p 3) in real serum samples.

16 essfully used for NSE determination in human serum samples.

17 sensitively detect biomarkers in low-volume serum samples.

18 measured in the gut mucosa, lung tissue, and serum samples.

19 filing of the cancer-associated T antigen in serum samples.

20 vatized in different pathological tissue and serum samples.

21 monstrated, measuring miRNA-492 in undiluted serum samples.

22 stics in an independent patient cohort using serum samples.

23 monstrated by detecting target DNA in spiked serum samples.

24 abel-free determining SCCA in clinical human serum samples.

25 tforms using a set of 223 well-characterized serum samples.

26 he fast, accurate assays of 100-fold diluted serum samples.

27 determination of MUC1 spiked to human blood serum samples.

28 shmania infantum antibodies in human and dog serum samples.

29 heart failure, in buffer and untreated human serum samples.

30 nd the robustness to quantify targets in 10% serum samples.

31 for the detection of AMP in the spiked human serum samples.

32 e source of O-glycans that we observe in the serum samples.

33 which is not highly sensitive on acute phase serum samples.

34 ternative to the Bio-Rad GM-EIA when testing serum samples.

35 ility for detection of alpha-syn oligomer in serum samples.

36 alciparum glutamate dehydrogenase (PfGDH) in serum samples.

37 minase autoantibodies found in 2 consecutive serum samples.

38 5846) of these proteins in individual plasma/serum samples.

39 eased IMMY sona Aspergillus LFA when testing serum samples.

40 post mortem human amygdala, as well as human serum samples.

41 of human control and TBI (acute and chronic) serum samples.

42 mic variants not observed in contemporaneous serum samples.

43 ) by qRT-PCR for selective expression in the serum samples.

44 ompting a proof-of-concept analysis of human serum samples.

45 tology, and cytokine levels were measured in serum samples.

46 sted the biochemical effects of CAR in human serum samples.

47 for anti-L. infantum up to 1:5120 in canine serum samples.

48 ed capillary electrophoresis (DSA-FACE) on a serum sample 1 week after LT.

49 ecognition patterns: group I consisted of 92 serum samples (10 preexposure and 82 postexposure serum

50 Of 84 serum samples, 28 were reactive with >=1 henipavirus gly

51 etic peptide (NT-proBNP) were measured using serum samples acquired and stored at time of CMR scan, a

52 used for analysis of interstitial fluid and serum samples after a subcutaneous injection of a therap

53 factors between fresh serum and re-dissolved serum samples after lyophilization.

54 hemical peaks by matching accurate mass from serum samples against a custom chemical database of 722

55 Screening of 1287 unique serum samples against four neurologic surface Ags (myeli

56 gorithm is demonstrated for correcting human serum samples analyzed by Fourier-transform mass spectro

57 onesterified FAs consistently measured in 50 serum samples analyzed independently by MSI-NACE-MS and

58 adalimumab monotherapy and had at least one serum sample and Psoriasis Area and Severity Index (PASI

59 o reasons: to collect only the IgEs from the serum sample and to enhance the optical interferometric

60 logy assays, we created a panel of 66 pooled serum samples and 66 pooled plasma samples generated fro

61 applied to a convenience set of 96 unexposed serum samples and a blinded set of 80 samples treated wi

62 ssed in seropositive patients with available serum samples and at least 2 years follow-up.

63 Furthermore, ddPCR experiments on serum samples and experiments with nuclease indicated th

64 asured by multiplex immunoassay and ELISA in serum samples and periodontal tissues.

65 ion, the device was evaluated using clinical serum samples and received a good correlation with large

66 We obtained serum samples and terminal ileum biopsies from 47 patien

67 nzyme immunoassay (IMMY GM-EIA) when testing serum samples and to identify the optimal galactomannan

68 We collected patient serum samples and used the capture-fusion assay to asses

69 used to evaluate the T-antigen expression in serum samples and was able to discriminate between contr

70 tions in the absence of a convalescent-phase serum sample, and provide the high-throughput testing re

71 994) who provide a vaginal self-swab sample, serum sample, and questionnaire yearly, we report a high

72 n (~5 muL), performs sample cleanup on human serum samples, and delivers a small volume out, for subs

73 n sample volumes are limited and/or numerous serum samples are being examined.

74 Zika-positive samples and healthy patients' serum samples, as well as 44 serum samples from enzyme-l

75 nthropometric data at 10-12 weeks and plasma/serum sampling at 16-18 weeks.

76 Sera from 763 representative subjects with serum samples available at all 3 ages were analyzed for

77 equency questionnaire and provided a fasting serum sample before study randomization (1985-1988).

78 We collected serum samples before 4-week intermittent fasting, at the

79 ble expression pattern of these genes across serum samples between different study groups.

80 We collected 2996 serum samples between May 2, and June 2, 2017, and we te

81 lio-oligosaccharides and mimics, the patient serum samples bound much more strongly to the gangliosid

82 Finally, ABBA serum samples but not control samples showed reactivity

83 d uninfected controls, IL-10 was measured in serum samples by means of enzyme-linked immunosorbent as

84 O-C4) and degradation (C4M) were assessed in serum samples collected 3, 6 and 12 months post-LT using

85 obulin M in 87% (52 of 60) COVID-19-positive serum samples collected 6 or more days after symptom ons

86 graphy-mass spectrometry to analyse maternal serum samples collected at 15- and 20-weeks' gestation f

87 Of the serum samples collected at the first time point, 15,398

88 Serum samples collected at the time of transplant showed

89 ic analyses, using liquid chromatography, of serum samples collected at time of admission to 12 North

90 y tandem mass spectrometry in 24 h urine and serum samples collected before and after nitisinone.

91 yzed PLA2R-AB in multiple, 1054 longitudinal serum samples collected before diagnosis of MN from 134

92 We measured NfL longitudinally in serum samples collected between June 8, 2012, and Dec 8,

93 All the subjects were adults, and serum samples collected during the discharge were tested

94 raft function (n = 70) who consented to have serum samples collected for research purposes during a r

95 Serum samples collected from 130 immunized monkeys at tw

96 Clinical serum samples collected from 17 positive Lassa fever cas

97 In an analysis of serum samples collected from a community clinic an avera

98 tion by IgE, IgG(4), and IgG was examined in serum samples collected from subjects undergoing AIT aga

99 ho-Clinical IgG assays in convalescent-phase serum samples collected more than 14 days post-symptom o

100 Serum samples collected preoperatively (week 0) and afte

101 Using sequential serum samples collected up to 94 d post onset of symptom

102 identification of >10,000 features from >200 serum samples collected upon clinical presentation.

103 50% of the background signal from undiluted serum samples compared to conventional methods, demonstr

104 fied by challenging the immunosensor against serum samples, compared to conventional enzyme-linked im

105 Analyses of HBeAg in serum samples (concentration ranging from 0.1 to 60 ng/m

106 and dried chemicals on the all-in-one chip, serum samples containing the target virus RNA were simpl

107 When tested on serum samples, CrAg LFA had sensitivity of 93% (95% CI 6

108 n data with antibody binding data from human serum samples demonstrated qualitative and quantitative

109 IgG antibody (CR3022) to SARS-CoV-2 in human serum samples, demonstrating the efficacy of these devic

110 We used serum samples derived from a cohort of patients with GBS

111 yielded a quantitative, linear response for serum samples diluted to as low as 1:1600 dilution.

112 gh sensitivity detection in buffer and human serum sample down to 600 zM and 20 aM, respectively, whi

113 taff, masked to study intervention, analysed serum samples for antibodies against PCV10 serotypes by

114 les (n=74) were collected for viral culture, serum samples for measurement of IgM/IgG levels (n=30),

115 ign with dual approaches of collecting human serum samples for testing was developed.

116 y in the Finnish Maternity Cohort (FMC) with serum samples from >800,000 women collected during pregn

117 ed multiple inflammatory mediators in serial serum samples from 13 PALF survivors with APAPo + N-acet

118 anonymous case/control study comprising 179 serum samples from 136 patients with invasive fungal dis

119 We evaluated 111 serum samples from 14 mammalian species from Namibia for

120 was measured by using Luminex technology in serum samples from 146 patients with severe AD (median E

121 To accomplish this, two serum samples from 20 kidney transplant candidates with

122 Biomarkers were analyzed in serum samples from 242 HF patients (study 1) and 150 pat

123 This nested case-control study used stored serum samples from 25 persons with tuberculosis up to 10

124 Serum samples from 277 transplant recipients were analyz

125 Serum samples from 30 children with a bacterial bloodstr

126 Human blood serum samples from 30 University of Pittsburgh Medical C

127 We measured antibodies in serum samples from 30,576 persons in Iceland, using six

128 Serum samples from 35 of the sepsis and 28 of the bypass

129 IgG assay with the Architect system to test serum samples from 356 patients receiving in-center hemo

130 Serum samples from 39 steroid-naive DMD boys 4 to <7 yea

131 pylori multiplex serologic assays to analyze serum samples from 4063 incident cases of CRC, collected

132 l trial period.Methods: We selected baseline serum samples from 462 CAMP subjects subsequently random

133 o 66 sequential epitopes on 5 milk proteins, serum samples from 47 subjects were evaluated before and

134 ds: From May 2014 to April 2017, we obtained serum samples from 529 patients with septic shock from 2

135 Serum samples from 54 people with suspected acute Zika v

136 We analyzed clinical data and serum samples from 55 individuals with SARS-CoV-2 infect

137 performed microRNA (miRNA) profiling in 318 serum samples from 69 liver transplant recipients enroll

138 s by enzyme-linked immunosorbent assay using serum samples from 70 patients with PDAC, from 36 indivi

139 IFA-negative dogs, and group IV consisted of serum samples from 8 Brucella canis IFA-positive and 10

140 M. hyopneumoniae ELISAs were compared using serum samples from 8-week-old cesarean-derived, colostru

141 identify candidate chemicals of interest in serum samples from 83 women FFs and 79 women office work

142 We analyzed serum samples from 90 patients with biopsy-proven CeD an

143 Finally, the presence of RC0497 in the serum samples from a cohort of humans presenting with ac

144 Serum samples from a total of 49 documented consecutive

145 measured the levels of 1,251 metabolites in serum samples from a unique and deeply phenotyped health

146 lly infected dogs, group III consisted of 26 serum samples from Bartonella PCR-negative and IFA-negat

147 th Bartonella spp., group II consisted of 36 serum samples from Bartonella PCR-positive naturally inf

148 terleukin-6 (IL-6) can be quantified in 2-uL serum samples from chimeric antigen receptor T cell (CAR

149 d screened a total of 180 well-characterized serum samples from cows assigned to 4 groups based on pr

150 althy patients' serum samples, as well as 44 serum samples from enzyme-linked immunosorbent assay (EL

151 ies immunoglobulin; and GCIRAB1, from pooled serum samples from healthy adults immunised with license

152 In addition, serum samples from healthy volunteers vaccinated with a

153 Cryopreserved serum samples from HIV-infected Ugandans obtained as par

154 ).METHODSWe performed targeted lipidomics on serum samples from individuals with familial coronary ar

155 oncept, this workflow was applied to patient serum samples from individuals with liver cirrhosis to a

156 Serum samples from JSLE patients and from healthy contro

157 Serum samples from malaria-naive adults, collected befor

158 this study we utilized lipidomics to analyze serum samples from mice exposed to various percentages o

159 chemokines (EMA) elevated in mid-gestational serum samples from mothers of children with autism and i

160 We analyzed 519 serum samples from participants in a phase 1 vaccine tri

161 We obtained serum samples from patients archived before a diagnosis

162 NA AAbs levels directly in 100-times diluted serum samples from patients diagnosed with RA and in jus

163 e in patients with CRVS.Methods: We analyzed serum samples from patients enrolled in the ATHOS-3 (Ang

164 We performed metabolomic analyses of serum samples from patients with cirrhosis at multiple c

165 2 (IgG) and 29 (neutralization) convalescent serum samples from patients with Covid-19, most of whom

166 The glycan score was tested in serum samples from patients with different pathologies,

167 Serum samples from patients with DOCK8 deficiency and at

168 We measured levels of cytokines in serum samples from patients with mild and severe acute p

169 spension bead arrays were applied to analyze serum samples from patients with OA (n = 273), control s

170 d required activation of NLRP3 (confirmed in serum samples from patients with pancreatitis).

171 ble endogenous contributors of the CSD using serum samples from patients with the CSD.

172 ing (based on the histologic analysis) using serum samples from patients with treated and healed CeD

173 Serum samples from patients with untreated CeD had the g

174 monoclonal antibody and various hyperimmune serum samples from ruminants.

175 We assessed sensitivity using 128 serum samples from symptomatic PCR-confirmed coronavirus

176 ic tests (RDTs) were assessed with Indian VL serum samples from the following clinical groups: paired

177 iphenyl (BB153) have been measured in pooled serum samples from the National Health and Nutrition Exa

178 We performed a cross-sectional study of 664 serum samples from the Oxford, Kiel and Brescia cohorts

179 The level of PlGF was estimated in 17 paired serum samples from the uterine vein (ipsilateral or cont

180 ed levels of fluoroethers and legacy PFAS in serum samples from Wilmington residents.

181 itis, metabolomic profiling was performed on serum; samples from 70 were in a training data set, and

182 samples (10 preexposure and 82 postexposure serum samples) from 10 adult beagles experimentally inoc

183 ming ELISAs from study 1 were compared using serum samples generated under field conditions.

184 5(OH)D(3)) concentrations were determined in serum samples harvested in November from ewes grazed out

185 zation of several autoantibodies in the same serum sample have been demonstrated for anti-thyroglobul

186 The measurements in clinical serum samples have shown that the native kinetic paramet

187 aluation of dual biosensor chip in untreated serum samples indicated favorable simultaneous detection

188 e determination of cytochrome c in the human serum sample is a regular medical investigation performe

189 quantification of four protein biomarkers in serum samples is demonstrated with the cPlate system, ac

190 The target anti-p53aAbs from human serum samples is selectively isolated and purified using

191 derived xenografts (PDXs), and DLBCL patient serum samples leveraging systems biology analyses and dr

192 n of IgE, compared to other analytes in real serum samples, made it necessary to use nanoparticles (N

193 e levels of RGS11 (in the range of pg/mL) in serum samples make it difficult to quantify using curren

194 lear magnetic resonance (1H-NMR) analysis of serum samples may be used as an objective method to disc

195 t sera (n = 31), CSFs (n = 11), longitudinal serum samples (n = 15), and using mAbs (n = 14) generate

196 er, NY), using a panel of serially collected serum samples (n = 224) from 56 patients with confirmed

197 ke were then measured in urine (n = 474) and serum samples (n = 451) from the European Prospective In

198 Serum samples (n = 5,369) were analyzed for anti-PEG-ASP

199 ofiling in both brain (n = 109) and matching serum samples (n = 566) to identify differentially expre

200 nsion cohorts at the same study site who had serum samples obtained at multiple early timepoints.

201 Serum samples obtained every 6 months were evaluated for

202 ospective case/control study, comprising 175 serum samples obtained from 131 patients, 35 of whom had

203 Serum samples obtained from a clinical trial in Western

204 lycans has been validated here with multiple serum samples obtained from different cohorts of colorec

205 We performed untargeted metabolomics on serum samples obtained from patients with IS (N = 508) a

206 tools on small RNA sequencing data set from serum samples of 12 healthy human controls, and COMPSRA

207 Serum samples of 16 athletes collected 24 h before, imme

208 laboratory data as well as CSF and/or blood serum samples of 237 participants, including 98 patients

209 Serum samples of 35 CSU patients (25 ASST-positive) and

210 In a prospective, multicentric study, serum samples of 616 patients with testicular GCTs and 2

211 geted metabolomic profiling was performed on serum samples of children with either FA alone, asthma a

212 the biosensor platform to detect miR-19b in serum samples of children, suffering from brain cancer,

213 Heparinase treatment of serial plasma and serum samples of patients undergoing transcoronary ablat

214 The direct binding from diluted serum samples of specific glycosylated-PSA to the first

215 eactive protein (CRP) and recovery in spiked serum samples of ~98%.

216 umor biomarker candidate) in undiluted human serum samples, operating with very low sample volumes (5

217 uplicate containing a total of 15 individual serum samples per group.

218 Serum samples pre-LT and 4-12 weeks post-LT (n = 117) we

219 after SBNET resection (n = 12), with serial serum sampling (preoperatively day 0; postoperatively at

220 isolation of infectious virus from semen and serum samples prospectively obtained from a cohort of pa

221 pletion of TRIM72 antibodies from these same serum samples rescues sarcolemmal repair capacity.

222 of 16.7 pM and 48.6 pM in spiked buffer and serum samples, respectively.

223 Analysis of PLA2R-AB in longitudinal serum samples revealed seropositivity in 44% (59 out of

224 Analysis of 130 prostate cancer patient serum samples revealed that some members of the protein

225 glycopeptides was developed and applied on a serum sample set from 185 healthy donors.

226 Testing of 192 human serum samples showed that DCL accurately identified pati

227 uccessfully applied in a cohort of 140 human serum samples, showing good sensitivity (64.6%) as well

228 uccessfully applied in a cohort of 127 human serum samples, showing good sensitivity (97.6%) as well

229 he technology platform was tested with human serum samples spiked with exosomes derived from healthy

230 he SALDI-MS results obtained on the desalted serum sample spots show both good reproducibility and co

231 From 2,196 serum samples submitted for CrAg testing, 96 cases were

232 rated for its practical application in human serum samples, suggesting a promising application potent

233 2D-IR spectra of blood serum samples supplemented with varying concentrations o

234 Untargeted metabolomics in serum samples taken at three different days after overni

235 ssified 456 out of the 457 COVID-19-negative serum samples tested (424 of them collected before the p

236 uding 66 APAP-related patients) had baseline serum samples tested for ferritin, transferrin, iron, an

237 Of 99 serum samples tested, 57 were CrAg positive (CrAg(+)) by

238 res in 91 out of 92 (98.9%) multiple myeloma serum samples tested.

239 A total of 1,200 serum samples that were tested for SARS-CoV-2 IgG antibo

240 mportant to eel aquaculture, we screened eel serum samples to determine their 17beta-estradiol concen

241 ternity Cohort found that they donated >2500 serum samples up to 12 years later.

242 s profitably engaged to detect uPA in spiked serum samples up to 9.2 pM.

243 outinely measure PSA concentrations in human serum samples, very low concentrations have to be monito

244 sensor offers a recovery index of 108%, when serum sample was spiked with a physiological concentrati

245 ct A. baumannii M3237 and 54149 from complex serum samples was demonstrated.

246 a DNA biosensor to detect ZIKV in real human serum samples was developed using an oxidized glassy car

247 In sequential pre- and post-COVID-19 serum samples, we confirmed autoAb seroconversion.

248 port zinc concentrations in individual donor serum samples; we demonstrate that they can provide resu

249 Serum samples were also available for these subjects.

250 Saliva and serum samples were also collected.

251 The biological effects of both serum samples were also compared on conjunctival and cor

252 Serum samples were also screened by means of enzyme-link

253 Serum samples were analyzed by gliadin antibody enzyme-l

254 Serum samples were analyzed by routine clinical test and

255 Serum samples were analyzed for antibodies against vacci

256 Aliquots of 30 patient serum samples were analyzed for creatinine, bilirubin, a

257 Both maternal and cord serum samples were assayed for levels of IgG1 and IgG3 s

258 Serum samples were collected and analyzed using liquid c

259 Serum samples were collected and tested for presence of

260 h active allograft dysfunction (n = 9) whose serum samples were collected as part of clinical care.

261 Clinical information and maternal serum samples were collected at three time points during

262 Serum samples were collected before, during, and after t

263 Serum samples were collected during second and third tri

264 Serum samples were collected for global metabolomic anal

265 Serum samples were collected on day 1, week 4, and week

266 Serum samples were collected over a median time period o

267 Serum samples were collected pre-injury, and 1 min-6 h f

268 Donor serum samples were evaluated by indirect immunofluoresce

269 arr virus (EBV) status was assessed, and 559 serum samples were evaluated for TARC, MDC, IL-10, and s

270 As a proof of concept, clinical serum samples were examined by trypsin-PRM, and a slight

271 All serum samples were extensively evaluated by using both n

272 tration values directly measured in 35 human serum samples were found closely correlated to those mea

273 In addition, serum samples were obtained at approximately 5, 30, and

274 -surgical periodontal treatment, and GCF and serum samples were obtained at baseline and at 6 weeks a

275 ents, 457 were repeatedly NAAT-negative, and serum samples were obtained for 18 such patients (6 COVI

276 Serum samples were quantified for circulating levels of

277 lycoprotein by >=1 serological method, and 6 serum samples were reactive against >=1 filovirus glycop

278 Subgingival plaque samples and serum samples were subjected to quantitative Polymerase

279 spirates, and sputum samples) in addition to serum samples were submitted and subjected to galactoman

280 representative ionic metabolites from human serum samples were successfully quantified.

281 All serum samples were tested for anti-ZIKV immunoglobulin G

282 gladeshi infants, available post-vaccination serum samples were tested for polio-neutralizing antibod

283 ssed culture supernatants, as well as paired serum samples were tested for the presence of HLA antibo

284 Serum samples were used to measure the levels of tumor n

285 diagnostic sensitivity by only 2.2% (1 of 46 serum samples) when combined with the IgG anti-BP180 enz

286 or has been used to estimate ALP in clinical serum samples, where the level was found to be 83.15 U/L

287 ty and selectivity to quantify ZIKV in human serum samples, which suggests its promising clinical app

288 nsor was successfully used with spiked human serum sample with a limit of detection of 81 pM This wor

289 riers or non-carriers), and had at least two serum samples with a time interval of 6 months or more.

290 tigen as a model protein target in 25 muL of serum samples with an unprecedented detection limit of 2

291 the practical detection of H(2)O(2) in human serum samples with desirable properties.

292 s validated with a large number of water and serum samples with excellent precision and recovery at q

293 ts the presence of Abeta aggregates in human serum samples with excellent sensitivity.

294 ng cancer metabolomics from 93 paired tissue-serum samples with magnetic resonance spectroscopy and i

295 etabolic profile of a total of 394 patients' serum samples with respect to their rs7903146 genotype u

296 d for glucose detection from human urine and serum samples with satisfactory results.

297 aches, the biomarkers were captured from the serum samples with the help of aptamer-coated magnetic b

298 developed MCFA system enabled to analyze 16 serum samples with the transferrin concentration from 90

299 tration of serotonin in 70 muL of mice blood serum samples without additional pretreatment.

300 West Nile viral IgM antibody levels in human serum samples yielding analyte detection limits comparab